G-Finder Report: DNDi calls for increase in global R&D funding for NTDs on the first World NTD Day

The annual G-FINDER report, published on the first World NTD Day, showed that global funding for neglected disease R&D rose to $4 billion in 2018, the highest level ever recorded, and the first time that funding has grown for three consecutive years. However, funding for NTDs has been essentially flat for the past decade. In fact, it has gone backwards: funding for these diseases was almost 10% lower in 2018 than it was 2009, dropping by $34m, or 9.1%.

DNDi welcomes the findings of the 2019 G-FINDER report

30 January 2019
Geneva, Switzerland
The annual G-FINDER report provides policy-makers, donors, researchers, and industry with a comprehensive analysis of global investment into R&D of new products to prevent, diagnose, control, or cure neglected diseases in developing countries. It gives an up-to-date analysis of how R&D investments are being allocated across 36 neglected diseases, and product types, funding trends over time, and where the potential gaps lie.

Brazil’s Ministry of Health and CNPq to invest in researching new treatments for leishmaniasis and Chagas disease

Brasilia, Brazil – 5 December 2019
Studies may lead to therapeutic alternatives for people living with these neglected tropical diseases
The Brazilian Ministry of Health (the Department of Science and Technology of the Science, Technology and Strategic Inputs Secretariat – Decit/SCTIE) and CNPq (National Council for Scientific and Technological Development) will invest around R$ 1,5 million (US$ 370,000) in research that may lead to the development of a new treatment option for cutaneous leishmaniasis.

DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness

Geneva/Seattle – 25  November 2019

DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.

Revolutionizing paediatric HIV treatment

29 November 2019
Geneva, Switzerland

  • This invitation-only event marks World AIDS Day and the end of DNDi’s multi-year Unitaid grant for the development and delivery of new paediatric HIV treatment formulations.

The French development agency AFD renews its support for the Drugs for Neglected Diseases initiative (DNDi) in researching and developing treatments for neglected tropical diseases

Paris, France – 18 October 2019
Bertrand Walckenaer, Deputy CEO of the Agence Française de Développement (AFD), and Dr Bernard Pécoul, Executive Director of DNDi, signed an agreement today for a project to support the research and development of treatments for neglected tropical diseases. Implementing a strategy to develop suitable, affordable, and safe treatments is a major international challenge; more than one billion people in 149 countries are affected by these diseases. This project is funded by a EUR 8 million grant.

L’Agence française de développement poursuit son soutien à Drugs for Neglected Diseases initiative (DNDi) pour appuyer la recherche et le développement de traitements contre les maladies tropicales négligées

Paris, France – le 18 octobre 2019
Bertrand Walckenaer, Directeur délégué de l’Agence française de développement, a signé, ce jour, avec Dr. Bernard Pécoul, Directeur exécutif de DNDi, un projet d’appui à la recherche et au développement de traitements contre les maladies tropicales négligées. La mise en place d’une stratégie de développement de traitements adaptés, abordables et sûrs est un enjeu majeur à l’échelle internationale : plus d’un milliard de personnes réparties dans 149 pays sont touchées par ces maladies. Le projet est une subvention d’un montant de 8 millions d’euros.

Tribune de Genève [17 September 2019]

“La cuvée de la Vigne des Nations 2018 soigne une organisation internationale” – “The 2018 vintage of ‘La Vigne des Nations’ heals an international organization”

Click here to read the article

Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.

TiaSáng [31 January 2019]

“Tài trợ cho nghiên cứu về những “căn bệnh bị lãng quên” tăng cao kỷ lục” – “Neglected disease research funding hits record high”

Click here to read the article